RxDoctor Payments Data

Lavea Landrum

Family · Duncanville, TXNPI 1457703779

Payments from drug & device makers

$340in general payments, 2019–2025

Across 18 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$72
  • Exact Sciences$52
  • Novo Nordisk$34
  • Teva Pharmaceuticals USA, Inc.$33
  • Pfizer$31
  • AbbVie$28
  • plus $89 from 5 others

What the payments were for

  • Food & beverage$340100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$340 in reported general payments places this provider in the 45th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$327,715
Medicare patients
544
Services billed
4,576

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide167$265,378
JardianceEmpagliflozin66$85,050
MounjaroTirzepatide38$58,985
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$42,594
RybelsusSemaglutide16$39,217
EntrestoSacubitril/Valsartan26$38,915
Divalproex Sodium400$35,210
EliquisApixaban42$35,007
FarxigaDapagliflozin Propanediol21$32,133
CaplytaLumateperone Tosylate12$29,503
Risperdal ConstaRisperidone Microspheres17$27,072
TrulicityDulaglutide15$19,911
LinzessLinaclotide15$16,677
Trazodone Hcl454$8,362
Duloxetine Hcl167$6,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$34$304,595183 claims
Lilly USA, LLCMounjaro, Trulicity, Olanzapine$20$80,46897 claims
GSKTrelegy Ellipta$16$42,59439 claims
PfizerEliquis$31$35,00742 claims
AbbVieLinzess$28$16,67715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 15,456 family providers in Texas.

Other family in Duncanville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →